Actinogen Medical Limited · ASX:ACW
Actinogen Medical — Investor Presentation (October 2017)
20 slides from Actinogen Medical's investor presentation, October 2017
Slide 1: Xanamem for Alzheimer's disease
Xanamem™ for Alzheimer’s disease Dr Bill Ketelbey CEO October 2017
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Actinogen Medical Limited. (“Actinogen” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to mak
Slide 3: Actinogen Medical
Actinogen Medical • Headquartered in Sydney, Australia. ASX:ACW STOCK METRICS* • Developing Xanamem for the treatment of ASX CODE ACW Alzheimer's disease (AD) and cognitive Market Capitalisation $35m impairment in chronic neurodegenerative Enterprise Value $32.0m diseases. 52-week High/Low $0.04-$0.
Slide 4: Commercially experienced, globally recognised
Commercially experienced, globally recognised Board of Directors Xanamem Clinical Advisory Board Dr. Geoff Brooke Dr. Bill Ketelbey Dr. Jason Loveridge Prof. Craig Ritchie Prof. Colin Masters Prof. Jeffrey Cummings Chairman CEO & MD Non-Executive Director Chair 4
Slide 5: Alzheimer's disease: a vast unmet medical need
Alzheimer’s disease: a vast unmet medical need • There are nearly 50 million Alzheimer's disease sufferers world-wide and the number is set to double every 20 years • It’s the leading cause of death in Australian women and second only to heart disease in Australia, overall • Of the top-ten leading f
Slide 6: Xanamem
Xanamem • A novel, first in class, potent, orally bioavailable, brain-penetrant, 11βHSD1 inhibitor • Differentiated mechanism of action: blocking cortisol production in the brain • Symptomatic and disease modifying effects in vivo • Well-tolerated: acceptable clinical safety, toxicity and PK/PD prof
Slide 7: Xanamem development indications
Xanamem development indications PRE-CLINICAL PHASE I PHASE II Alzheimer’s disease Diabetes cognitive impairment Post traumatic stress disorder Post myocardial infarction 7
Slide 8: Cortisol: a validated biomarker and target for AD
Cortisol: a validated biomarker and target for AD Cortisol and Alzheimer’s • Recent independent studies support the association between cortisol and development and progression of Alzheimer's disease 1-5 • Cognitive impairment in patients with neuroendocrine dysfunction 6-9 • Compelling evidence pro
Slide 9: Mechanism of action
Mechanism of action Xanamem binds to 11βHSD1, reducing brain cortisol production 9
Slide 10: Xanamem
Xanamem Symptomatic and disease modifying effects in mouse models Cognition: treatment 28 days Amyloid Clearance: treatment 28 days Control 43 ± 21 Control 38 ±3 Treatment Treatment p=0.004 172 ± 28 p=0.01 22 ±5 0 50 100 150 200 250 0 10 20 30 40 50 Latency to enter dark compartment (seconds) Number
Slide 11: Clinical Development
Clinical Development 11 Investor Presentation October 2017
Slide 12: Xanamem journey of discovery
Xanamem journey of discovery Diabetes Cognition Phase II 11β-HSD1 is highly expressed in XanADu First Subject In regions important for cognition Carbenoxolone is Xanamem data shown to enhance published cognitive function Webster et al., 2017 11β-HSD1 in elderly men and First First Xanamem XanADu typ
Slide 13: Xanamem completed clinical studies
Xanamem completed clinical studies (Building on extensive historic 11βHSD1 class safety data from metabolic disease research) A phase I single A phase I multiple A phase I single-dose A phase I CSF/ ascending dose (SAD) ascending dose (MAD) fed-fasted crossover plasma pharmacokinetic study1 study1 s
Slide 14: Xanadu Phase II trial
Xanadu Phase II trial Phase II double blind, randomised, placebo-controlled study to assess the efficacy and safety of Xanamem in participants with mild Alzheimer's disease* • 34 patients enrolled (end-Sept) and first patient has already completed study. • All 20 study sites open and patients enroll
Slide 15: Xanamem secondary indication – DCI
Xanamem secondary indication – DCI Diabetes-related mild Cognitive Impairment • Several potential secondary indications considered • DCI selected due to a strategic mix of scientific, clinical, and commercial factors • Type 2 Diabetes Mellitus (T2DM) is a significant risk factor for cognitive impair
Slide 16: Commercial
Commercial 16 Investor Presentation October 2017
Slide 17: Value proposition
Value proposition • Strong therapeutic rationale, differentiated mechanism of action • Differentiated from, but complementary to anti-Aβ, anti-Tau and other AD therapeutic strategies • Solid non-clinical and clinical data set • First in class compound, designed for brain penetration • 11βHSD1 class
Slide 18: Peer comparison
Peer comparison What big pharma 2000 companies are paying 1800 for acquisition of drug 1600 developers in the VALUE US$ MILLIONS 1400 X Alzheimer’s space 1200 1000 800 X 600 X 400 200 0 PH I PH II PH III 18
Slide 19: Summary
Summary • A novel, first in class, potent, orally bioavailable, brain-penetrant, 11βHSD1 inhibitor • Strong therapeutic rationale, differentiated mechanism of action: blocking cortisol production in the brain • Symptomatic and disease modifying effects in vivo • Well-tolerated: acceptable clinical s
Slide 20: Dr. Bill Ketelbey, CEO & Managing Director
Dr. Bill Ketelbey CEO & Managing Director ☏ Main: +61 2 8964 7401 ✉Email: bill.ketelbey@actinogen.com.au
Actinogen Medical — Investor Presentation (October 2017) on 6ix